Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.
Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Torka P, et al. Among authors: sundaram s. Blood Adv. 2020 Jan 28;4(2):253-262. doi: 10.1182/bloodadvances.2019000875. Blood Adv. 2020. PMID: 31945157 Free PMC article.
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies.
Ghione P, Gu JJ, Attwood K, Torka P, Goel S, Sundaram S, Mavis C, Johnson M, Thomas R, McWhite K, Darrall A, DeMarco J, Kostrewa J, Mohr A, Rivas L, Neiders M, Suresh L, Segal BH, Griffiths EA, Ramsperger V, Shen L, Hernandez-Ilizaliturri FJ. Ghione P, et al. Among authors: sundaram s. Blood. 2021 Sep 2;138(9):811-814. doi: 10.1182/blood.2021012443. Blood. 2021. PMID: 34189565 Free PMC article. No abstract available.
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.
Torka P, Akhtar OS, Reddy NM, Baysal BE, Kader A, Groman A, Nichols J, Mavis C, Tario JD, Block AW, Sait SNJ, Ghione P, Sundaram S, Przespolewski ER, Mohr A, Lund I, Kostrewa J, McWhite K, DeMarco J, Johnson M, Darrall A, Thomas-Talley RN, Wallace PK, Neppalli V, Hutson A, Hernandez-Ilizaliturri FJ. Torka P, et al. Among authors: sundaram s. Cancer. 2022 Apr 15;128(8):1595-1604. doi: 10.1002/cncr.34106. Epub 2022 Feb 14. Cancer. 2022. PMID: 35157306 Free PMC article. Clinical Trial.
Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
Torka P, Groman A, Wong J, Nichols J, Kader A, Mavis C, Anampa-Guzmán A, Sait SJ, Block A, Przespolewski E, Mohr A, Lund I, McWhite K, Kostrewa J, DeMarco J, Johnson M, Darrall A, Thomas R, Sundaram S, Ghione P, Hutson A, Hernandez-Ilizaliturri FJ. Torka P, et al. Among authors: sundaram s. Blood Adv. 2023 Apr 11;7(7):1146-1155. doi: 10.1182/bloodadvances.2022008543. Blood Adv. 2023. PMID: 36375132 Free PMC article. Clinical Trial.
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.
Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P. Agrawal P, et al. Among authors: sundaram s. Leuk Lymphoma. 2023 May;64(5):1026-1034. doi: 10.1080/10428194.2023.2191152. Epub 2023 Mar 24. Leuk Lymphoma. 2023. PMID: 36960939
1,149 results